Lipid Management in Clinical Practice (MK-0524A-115)
This study has been completed.
Information provided by (Responsible Party):
First received: February 17, 2010
Last updated: February 1, 2012
Last verified: February 2012
The aim of this observational program is to generate data on the use of Tredaptive (nicotinic acid/laropiprant) for lipid management under routine medical practice conditions.
Lipid Metabolism Disorder
|Study Design:||Time Perspective: Prospective|
|Official Title:||Lipid Management in Clinical Practice|
Resource links provided by NLM:
Further study details as provided by Merck:
Primary Outcome Measures:
- Number of Participants With Lipid Panel Control [ Time Frame: From Visit 1 entrance evaluation (Week 0) to Visit 2 (between Weeks 8-22) ] [ Designated as safety issue: No ]Lipid Panel Control was defined as achieving target for one or more of the following parameters: low-density lipoprotein cholesterol (LDL-C) at goal (<100mg/dL), high-density lipoprotein cholesterol (HDL-C) within normal range (40mg/dL for males and 50mg/dL for females), and/or triglycerides within normal range (≤ 150mg/dL).
Secondary Outcome Measures:
- Number of Participants Who Reported Adverse Events [ Time Frame: Up to 22 weeks ] [ Designated as safety issue: Yes ]
|Study Start Date:||October 2009|
|Study Completion Date:||February 2011|
|Primary Completion Date:||February 2011 (Final data collection date for primary outcome measure)|
Patients treated within a disease management program
Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
Patients treated outside a disease management program
Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
Contacts and Locations